Healthcare / Drug Manufacturers - Specialty & GenericKuala Lumpur
$2.11
+0.01 (+0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $40.6M · quality 71.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$299M
P/E
12.4x
↓EV/EBITDA
3.5x
↓ROE
6.0%
↑Gross Margin
44.1%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.0%
FCF CAGR
+5.4%
FCF margin
14.1%
FCF / Net income
2.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $365.1M · net income $25.0M · FCF $51.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $365.1M | $365.1M | $368.7M | $355.0M | $334.2M |
| Net Income | $25.0M | $25.0M | $26.7M | $37.3M | $34.5M |
| EBITDA | $57.1M | $57.1M | $58.2M | $71.8M | $64.6M |
| EPS | — | — | 0.19 | 0.26 | 0.24 |
| Gross Margin | 44.1% | 44.1% | 42.4% | 43.4% | 43.2% |
| Operating Margin | 10.2% | 10.2% | 11.1% | 15.4% | 14.4% |
| Net Margin | 6.9% | 6.9% | 7.2% | 10.5% | 10.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.13 | 0.13 | 0.09 |
| Current Ratio | 5.43 | 5.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $51.5M | $51.5M | $40.6M | $550000.00 | $44.0M |
| Returns | |||||
| ROE | 6.0% | 6.0% | 6.5% | 9.4% | 9.3% |
| Valuation | |||||
| P/E | 12.41 | 12.41 | 12.12 | 8.84 | 10.53 |
| EV/EBITDA | 3.53 | 3.53 | 4.08 | 3.52 | 4.11 |
| P/B | 0.72 | 0.72 | 0.79 | 0.83 | 0.98 |
| Growth & Yield | |||||
| Revenue Growth | -1.0% | -1.0% | 3.8% | 6.2% | — |
| EPS Growth | — | — | -28.6% | 8.0% | — |
| Dividend Yield | 5.2% | 5.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.4%
Start / end P/E
n/dx → n/dx
EPS bridge
0.19 → n/d
Residual
-6.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.